Direct T-cell Presentation by cDC1: The Key Feature for Cancer Vaccine Success? - CRCL-Ciblage thérapeutique de la tumeur et de son environnement immunitaire Accéder directement au contenu
Article Dans Une Revue Cancer Immunology Research Année : 2022

Direct T-cell Presentation by cDC1: The Key Feature for Cancer Vaccine Success?

Résumé

Abstract In this issue of Cancer Immunology Research, Ferris and colleagues demonstrate that type 1 conventional DC (cDC1) vaccines drive tumor rejection through direct antigen presentation, without the need of endogenous cDC1. This suggests that cDC1-based vaccines could represent an optimal strategy to induce antitumor immunity in patients. See related article by Ferris et al., p. 920 (7) .

Dates et versions

hal-03783998 , version 1 (22-09-2022)

Identifiants

Citer

Margaux Hubert, Christophe Caux, Jenny Valladeau-Guilemond. Direct T-cell Presentation by cDC1: The Key Feature for Cancer Vaccine Success?. Cancer Immunology Research, 2022, 10 (8), pp.918-918. ⟨10.1158/2326-6066.CIR-22-0473⟩. ⟨hal-03783998⟩
14 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More